Isabl integrates the whole genome and transcriptome to inform cancer care.
Isabl specializes in the fields of whole-genome cancer diagnostics. The company is currently looking to partner with oncology centers nationwide to showcase the value of using whole-genome sequencing in clinical cancer care.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 18, 2022 | Seed | $3M | 4 | Two Sigma Ventures | — | Detail |
Jun 1, 2020 | Series Unknown | — | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Two Sigma Ventures | Yes | Seed |
Milad Alucozai | — | Seed |
Sand Hill Angels | — | Seed |
Y Combinator | — | Seed |
Bossanova Investimentos | — | Series Unknown |